Inclusion Criteria:

          -  Participants must have relapsed or refractory plasmablastic lymphoma or ALK+ large
             Bcell lymphoma by WHO criteria.

          -  Participants must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter [LDi] to be recorded
             for non-nodal lesions and short axis for nodal lesions) as ≥15 mm in LDi for nodal
             disease or ≥10 mm in LDi for extranodal lesions.

          -  Participants must have received prior systemic lymphoma therapy.

          -  Age ≥18 years. Because no dosing or adverse event data are currently available on the
             use of belantamab mafodotin in participants <18 years of age, children are excluded
             from this study.

          -  ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A).

          -  Participants must have adequate marrow function as defined below (unless abnormalities
             are considered related to marrow and/or splenic involvement by lymphoma):

               -  absolute neutrophil count ≥1,000/mcL

               -  platelets ≥50,000/mcL

               -  hemoglobin ≥ 8.0 g/dL

          -  Participants must have adequate organ function as defined below:

               -  total bilirubin ≤ 1.5 X institutional upper limit of normal (ULN); (Isolated
                  bilirubin ≥1.5xULN is acceptable if bilirubin is fractionated and direct
                  bilirubin <35%)

               -  AST(SGOT)/ALT(SGPT) ≤2.5 × institutional ULN

               -  Spot urine (albumin/creatinine) <500 mg/g (56 mg/mmol) OR

               -  Urine Dipstick Negative/trace (if ≥1+ only eligible if confirmed ≤ 500 mg/g (56
                  mg/mmol) by albumin/creatinine ratio (spot urine from first void)

               -  Glomerular filtration rate (eGFR)≥30 mL/min/1.73 m2 (MDRD Formula).

          -  Participants with known history or current symptoms of cardiac disease, or history of
             treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac
             function using the New York Heart Association Functional Classification. To be
             eligible for this trial, participants should be class 2B or better.

          -  Belantamab mafodotin is potentially teratogenic. A female participant is eligible to
             participate if she is not pregnant or breastfeeding. Women of child-bearing potential
             must agree to use adequate contraception (hormonal or barrier method of birth control;
             abstinence) prior to study entry, for the duration of study participation, and for at
             least 4 months after the last dose of study intervention. Women must also agree not to
             donate eggs (ova, oocytes) for the purpose of reproduction during this period. Should
             a woman become pregnant or suspect she is pregnant while she or her partner is
             participating in this study, she should inform her treating physician immediately.
             Nonchildbearing potential is defined as follows (by other than medical reasons):

               -  ≥45 years of age and has not had menses for >1 year

               -  Patients who have been amenorrhoeic for <2 years without history of a
                  hysterectomy and oophorectomy must have a follicle stimulating hormone value in
                  the postmenopausal range upon screening evaluation

               -  Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation.
                  Documented hysterectomy or oophorectomy must be confirmed with medical records of
                  the actual procedure or confirmed by an ultrasound. Tubal ligation must be
                  confirmed with medical records of the actual procedure.

          -  Women of childbearing potential must have a negative highly sensitive serum pregnancy
             test, and agree to repeat highly sensitive serum pregnancy testing within 72 hours
             before the first dose of study intervention (if screening pregnancy test was not
             within 72 hours of dosing).

          -  Men treated or enrolled on this protocol must also agree to use adequate contraception
             prior to the study, for the duration of study participation, and 6 months after
             completion of administration. Men must also agree not to donate sperm during this
             period. Men may agree to remain abstinent from heterosexual intercourse as their
             preferred and usual lifestyle (abstinent on a long term and persistent basis) OR agree
             to use a male condom, even if they have undergone a successful vasectomy and female
             partner to use an additional highly effective contraceptive method with a failure rate
             of <1% per year when having sexual intercourse with a WOCBP (including pregnant
             females).

          -  Participants with a prior or concurrent malignancy whose natural history or treatment
             does not have the potential to interfere with the safety or efficacy assessment of the
             investigational regimen are eligible for this trial at the discretion of the overall
             PI.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Participants must not have current corneal epithelial disease except mild changes in
             corneal epithelium.

          -  Participant must not have current unstable liver or biliary disease defined by the
             presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or
             gastric varices, persistent jaundice, or cirrhosis. Note: Stable non cirrhotic chronic
             liver disease (including Gilbert's syndrome or asymptomatic gallstones) or
             hepatobiliary involvement of malignancy is acceptable if otherwise meets entry
             criteria.

          -  Participants who have not recovered from adverse events due to prior anti-cancer
             therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia. At
             the discretion of the overall PI, participants with residual toxicities > Grade 1 may
             be considered eligible if in the opinion of the overall PI the residual toxicity is
             not likely to interfere with the safety or efficacy assessment of the investigational
             regimen.

          -  Participants who are receiving any other investigational agents.

          -  Participants must not have central nervous system involvement by lymphoma, as
             belantamab mafodotin is not known to penetrate the CNS.

          -  Participant must not use contact lenses while participating in this study.

          -  Participant must not be simultaneously enrolled in any interventional clinical trial.

          -  Participant must not have used an investigational drug or approved systemic lymphoma
             therapy within 14 days or five half-lives, whichever is shorter, preceding the first
             dose of study drug. Steroids are permitted.

          -  Participant must not have had major surgery within 4 weeks of initiating study
             treatment.

          -  Participant must not have any evidence of active mucosal or internal bleeding.

          -  Participants must not have known immediate or delayed hypersensitivity reaction or
             idiosyncratic reactions to belantamab mafodotin or drugs chemically related to
             belantamab mafodotin, or any of the components of the study treatment.

          -  Participants must not have an uncontrolled intercurrent illness.

          -  Participant must not have an uncontrolled active infection.

          -  Participant must not have evidence of cardiovascular risk including any of the
             following:

               -  Evidence of current clinically significant uncontrolled arrhythmias, including
                  clinically significant ECG abnormalities such as 2nd degree (Mobitz Type II) or
                  3rd degree atrioventricular (AV) block.

               -  History of myocardial infarction, acute coronary syndromes (including unstable
                  angina), coronary angioplasty, or stenting/bypass grafting within three (3)
                  months of Screening.

               -  Class III or IV heart failure as defined by the New York Heart Association
                  functional classification system [NYHA, 1994].

               -  Participant must not have uncontrolled hypertension defined as persistent
                  systolic BP >160 mmHg or diastolic BP >100 mmHg.

          -  Participant must not have psychiatric illness/social situations that would limit
             compliance with study requirements. Participants must not have any serious and/or
             pre-existing medical or other condition (including lab abnormalities) that could
             interfere with participant's safety in the opinion of the investigator.

          -  Women who are pregnant or lactating are excluded from this study because belantamab
             mafodotin can cause embryo-fetal harm when administered to a pregnant woman. Because
             there is an unknown but potential risk for adverse events in nursing infants secondary
             to treatment of the mother with belantamab mafodotin, breastfeeding should be
             discontinued if the mother is treated with belantamab mafodotin.

          -  Participant must not have presence of hepatitis B surface antigen (HBsAg), or
             hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose
             of study treatment. Patients with presence of HBsAg, but demonstrate both HBSag and
             HBV PCR negativity will be eligible for the study. Participant must not have positive
             hepatitis C antibody test result or positive hepatitis C RNA test result at screening
             or within 3 months prior to first dose of study treatment. Note: Participants with
             positive Hepatitis C antibody due to prior resolved disease can be enrolled, only if a
             confirmatory negative Hepatitis C RNA test is obtained. Note: Hepatitis RNA testing is
             optional and participants with negative Hepatitis C antibody test are not required to
             also undergo Hepatitis C RNA testing.

          -  Participant must not have uncontrolled HIV infection. HIV-infected patients on
             effective anti-retroviral therapy are eligible if they (1) have an undetectable viral
             load within the prior 6 months, or (2) have a detectable viral load with an absolute
             CD4 count of 200 cells per microliter or higher.

          -  Participant must not have invasive malignancies other than disease under study, unless
             the second malignancy has been medically stable for at least 2 years and, in the
             opinion of the principal investigators, will not affect the evaluation of the effects
             of clinical trial treatments on the currently targeted malignancy. Participants with
             adequately treated basal, squamous cell carcinoma or non-melanomatous skin cancer,
             carcinoma in situ of the cervix, superficial bladder cancer not treated with
             intravesical chemotherapy or BCG within 6 months, localized prostate cancer and PSA
             <1.0 mg/dL on 2 consecutive measurements at least 3 months apart with the most recent
             one being within 4 weeks of study entry, may be enrolled without a 2-year restriction.

          -  Participant must not have had plasmapheresis within 7 days prior to first dose of
             study treatment

          -  Participant must not have received prior treatment with a monoclonal antibody within
             30 days of receiving the first dose of study drugs